Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia PharmaTSE:4579 +0.17%58 Debt-to-Equity is 0.34 as of Jun. 2026, which is 750% above its 10-year median of 0.04. GuruFocus rates TSE:4579 with a GF Score™ of 58/100 and a GF Value™ of 円748.44 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Biotechnology companies, RaQualia Pharma ranks worse than 66.49% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for RaQualia Pharma's Debt-to-Equity or its related term are showing as below:
TSE:4579'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.68
Current: 0.34
During the past 13 years, the highest Debt-to-Equity Ratio of RaQualia Pharma was 0.68. The lowest was 0.00. And the median was 0.04.
TSE:4579's Debt-to-Equity is ranked worse than 66.49% of 955
companies
in the Biotechnology industry
Industry Median: 0.16
vs TSE:4579: 0.34
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
RaQualia Pharma Debt-to-Equity Related Terms
RaQualia Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, RaQualia Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Debt-to-Equity of 0.34 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on RaQualia Pharma and its competitors. This is 750% above median its historical median of 0.04. According to the industry distribution chart, RaQualia Pharma ranks #635 out of 955 companies in the Biotechnology industry, placing it in the top 66.5%.
Is RaQualia Pharma's Debt-to-Equity too high?
RaQualia Pharma's current Debt-to-Equity of 0.34 is 750% above median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. RaQualia Pharma's value of 0.34 is 112.5% above this industry median. Based on the distribution chart, RaQualia Pharma ranks #635 out of 955 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #635 out of 955 companies for Debt-to-Equity. This places RaQualia Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. RaQualia Pharma's value of 0.34 is 112.5% above this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.16, RaQualia Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Debt-to-Equity of 0.34 is 112.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Debt-to-Equity is 0.34, which is 750% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Modestly Undervalued. The stock's GF Value™ is 円748.44, compared to a current price of 円573.00 — trading 23.4% below its estimated fair value. The current Debt-to-Equity is 0.34, which is 750% above median its 10-year median of 0.04 and 112.5% above the Biotechnology industry median of 0.16. RaQualia Pharma's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Debt-to-Equity is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円573.00 is trading 23.4% below its estimated GF Value™ of 円748.44.
GuruFocus considers RaQualia Pharma to be Modestly Undervalued.
Key valuation signals for TSE:4579:
Debt-to-Equity: 0.34 (750% above median its 10-year median of 0.04)
GF Value™: 円748.44 vs. price of 円573.00 (23.4% below fair value)
Industry Position: 112.5% above the Biotechnology median (#635 of 955)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
58GF Score
Get the complete analysis for TSE:4579
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
